Anja Bialkowski1, Christian F Poets1, Axel R Franz2. 1. Department of Neonatology, University Children's Hospital of Tübingen, University of Tübingen, Tübingen, Germany. 2. Department of Neonatology, University Children's Hospital of Tübingen, University of Tübingen, Tübingen, Germany Center for Pediatric Clinical Studies, University Children's Hospital of Tübingen, University of Tübingen, Tübingen, Germany.
Abstract
BACKGROUND: Congenital chylothorax (CCT) is a rare disease of unknown aetiology. Treatment approaches vary; none has been evaluated prospectively. OBJECTIVE: To prospectively determine incidence, treatment and outcome of infants with CCT born in Germany in 2012. DESIGN: CCT was defined as non-traumatic chylous pleural effusion within 28 days after birth. As part of the Surveillance Unit for Rare Pediatric Conditions in Germany (Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland), all paediatric departments (n=432) received monthly reporting cards to notify the study centre of CCT cases, which were analysed based on anonymised questionnaires and discharge summaries. Data are shown as median (range) or n/N. RESULTS: Of 37 cases reported, 28 met inclusion criteria. Questionnaires and/or discharge summaries were available for 27/28. Assuming complete reporting, the incidence of CCT was 1:24 000. Nine infants suffered from proven or suspected syndromal anomalies, most frequently Noonan syndrome (5/9). Postnatally, 23 required mechanical ventilation, 3 continuous positive airway pressure; only 1 had no respiratory support. 17 infants were treated with inotropes/vasopressors, 25 required pleural drainage for 11 (1-36) days. In 13 infants, enteral feeds were withheld initially; 25 received medium-chain triglyceride diet at some time, 9 were treated with octreotide or somatostatin. 18 infants survived without, 6 with sequelae attributable to the underlying disorder; 3 infants died (median age at death 37 (2-144) days). Duration of hospital stay in survivors was 51 (20-127) days. Infants treated with octreotide or somatostatin had similar outcomes compared with those not treated. CONCLUSIONS: Based on this small observational study, CCT seems to have a favourable prognosis if not associated with genetic disorders. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Congenital chylothorax (CCT) is a rare disease of unknown aetiology. Treatment approaches vary; none has been evaluated prospectively. OBJECTIVE: To prospectively determine incidence, treatment and outcome of infants with CCT born in Germany in 2012. DESIGN:CCT was defined as non-traumatic chylous pleural effusion within 28 days after birth. As part of the Surveillance Unit for Rare Pediatric Conditions in Germany (Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland), all paediatric departments (n=432) received monthly reporting cards to notify the study centre of CCT cases, which were analysed based on anonymised questionnaires and discharge summaries. Data are shown as median (range) or n/N. RESULTS: Of 37 cases reported, 28 met inclusion criteria. Questionnaires and/or discharge summaries were available for 27/28. Assuming complete reporting, the incidence of CCT was 1:24 000. Nine infants suffered from proven or suspected syndromal anomalies, most frequently Noonan syndrome (5/9). Postnatally, 23 required mechanical ventilation, 3 continuous positive airway pressure; only 1 had no respiratory support. 17 infants were treated with inotropes/vasopressors, 25 required pleural drainage for 11 (1-36) days. In 13 infants, enteral feeds were withheld initially; 25 received medium-chain triglyceride diet at some time, 9 were treated with octreotide or somatostatin. 18 infants survived without, 6 with sequelae attributable to the underlying disorder; 3 infants died (median age at death 37 (2-144) days). Duration of hospital stay in survivors was 51 (20-127) days. Infants treated with octreotide or somatostatin had similar outcomes compared with those not treated. CONCLUSIONS: Based on this small observational study, CCT seems to have a favourable prognosis if not associated with genetic disorders. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: María Soriano-Ramos; Elena Orellana-Felis; María Teresa Moral-Pumarega; María López-Maestro; Concepción de Alba-Romero; Alberto Galindo-Izquierdo; Carmen Rosa Pallás-Alonso Journal: Indian J Pediatr Date: 2019-04-22 Impact factor: 1.967
Authors: Darius Ebrahimi-Fakhari; Eli Freiman; Monica H Wojcik; Katie Krone; Alicia Casey; Ariel S Winn; Amy E Roberts; Beth D Harper Journal: J Pediatr Date: 2017-03-28 Impact factor: 4.406
Authors: M Dorsi; A Giuseppi; F Lesage; J Stirnemann; L De Saint Blanquat; M Nicloux; Z Assaf; N Khen Dunlop; E Kermorvant-Duchemin; J-F Magny; Y Ville; A Lapillonne Journal: J Perinatol Date: 2017-10-19 Impact factor: 2.521